NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » TAKEDA Pharmaceutical Company back to previous page show list

TAKEDA Pharmaceutical Company

»
address: UK Address:
Takeda Global R & D Centre (Europe)Ltd
Arundel Great Court
2, Arundel Street,
London WC2 3DA
contact: www.takedo.com

Tel: 0044 (0) 207 759 5000

Fax: 0044 (0) 207 759 5270
key person: Chairman Kunio Takeda
President Yasuchika Hasegawa

Senior Managing Director Makoto Yamaoka
General Manager
Pharmaceutical Marketing Division

Managing Director Hiroshi Akimoto,Ph.D.

Managi

trunover in millions USD: 10360
R & D turnover in millions USD: 1450
NET profit: 2677
year of financial results: 2006
employees: 15069

active in China: YES
partner in China: Tianjin Takeda Pharmaceuticals Co., Ltd.

No. 11, Xinghua Road, Tianjin Xiqing, Economic Development Area, Tianjin, China TEL: +86-22-2397-0011
FAX: +86-22-2397-2230
Manufacture and sale of pharmaceuticals

SFDA approved: NO

Approvals:
GLP: YES
GMP: YES
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: YES
Active Pharmaceutical: NO
R&D: YES
Ingredients: NO
Western Generics: NO
TCM: NO

R & D:
Discovery: YES
Work Up (pilot to production): YES
Analysis: YES
Quality Control: YES
Stability: YES
Batch Release: YES

Clinical trials:
Run/Manage: YES
Data management: YES
Support Labs: YES

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: YES
Pharmaceuticals: YES
Agrochemicals: YES
Industrial & Other Chemicals: YES
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: YES

test:
R&D: YES
 
Overview
Takeda is a research-based global company with its main focus on pharmaceuticals. It is the largest pharmaceutical company in Japan and among the leaders in the world. Takeda discovers, develops, manufactures and markets a broad range of superior pharmaceutical products to strive toward better health for individuals and progress in medicine.
 
Takeda's Businesses

Takeda is a research-based global company with its main focus on pharmaceuticals.
Pharmaceuticals

Ethical Drugs
Ethical drugs are Takeda's core business, constituting about 81.5% of total net sales. Our two research centers in Japan conduct basic and applied research to create new breakthrough drugs. Development operations in Japan, the U.S. and Europe then work to move these drugs swiftly through development so that better treatments can be delivered as early as possible to patients around the world.

Takeda has an international marketing network including Japan and 13 overseas bases in the U.S., Europe and Asia. From these bases, Takeda markets its original products such as the anti-prostatic cancer agent leuprolide acetate (marketed as Lupron Depot®, Enantone®, Prostap® and Leuplin®), the anti-peptic ulcer agent lansoprazole (marketed as Prevacid®, Ogast®, Takepron® and other names), the anti-hypertensive agent candesartan cilexetil (marketed as Blopress®, Kenzen® and Amias®) and the anti-diabetic agent pioglitazone hydrochloride (marketed as Actos®). Including sales through licensees, Takeda's pharmaceuticals are available in over 100 countries worldwide.

Our production network includes the Hikari, Osaka and Shonan plants in Japan, as well as Takeda Ireland Ltd., which was newly established in 1997 and manufactures drugs for the European and U.S. markets. In addition, Takeda has two production facilities in Asia.

Consumer Healthcare

In Japan, Takeda has also built a strong presence in the over-the-counter (OTC) drug market, in which we now hold the number-two domestic share. The increasing emphasis on self-medication among Japanese consumers should help drive further growth in this field. By taking the viewpoint of consumers, we provide products and services that are closely matched to consumer needs.

Our main brands in the Consumer Healthcare segment are well recognized among Japanese consumers and include Alinamin® (vitamin B1 derivative preparations, etc.), Benza® (cold remedies), Hicee® (vitamin C preparations). 

Life-Environment business

On April 1,2005,Takeda transfered its life-environment business to Osaka Gas Chemicals Co., Ltd.
On April 1,2003,Takeda established a fully owned subsidiary Japan Enviro Chemicals,Ltd.

Agro business

On November 1,2002,Takeda and Sumitomo Chemical Co.,Ltd. established a joint venture Sumitomo Chemical Takeda Agro Company by merging agrochemical business.

Food business

On April 1, 2002, Takeda and Kirin Brewery Company, Ltd. established a joint venture Takeda Kirin Foods Corporation by merging food business.

Urethane chemicals
On April 1, 2001, Takeda and Mitsui Chemicals, Inc. established a joint venture Mitsui Takeda Chemicals, Inc. by merging two parties' urethane chemicals and composite materials businesses.

Bulk vitamin business

On Janyary 4, 2001, Takeda and BASF Japan Ltd. established a joint venture BASF Takeda Vitamins K.K.. On January 4, 2001, Takeda transferred all the shares of the following subsidiaries to BASF: Takeda Vitamin & Food USA, Inc., Takeda Canada Vitamin and Food Inc., Takeda Europe GmbH, and Takeda Vitamin & Food Asia Pte. Ltd.

Animal health business

On June 30, 2000, Takeda transferred its animal health business to a newly established joint venture, Takeda Schering-Plough Animal Health K.K.
Takeda in China
 
Takeda Pharmaceuticals (Tianjin) Co., Ltd. was set up in 1996 by joint venture of Takeda Pharmaceutical Company Limited and Tianjin Lisheng Pharmaceutical Co.Ltd.
The total investment of the company is USD 26.2 million with more than 300 employees.
Takeda has ten offices in China to cover the Chinese market.
 
 
 

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.